Two ongoing Phase 2 clinical trials of CPX-351 to be showcased

Download PDF Copy

Reviewed

Sep 4 2009

Celator Pharmaceuticals today announced that Scott Jackson, chief executive officer, is scheduled to present at the Thomas Weisel Partners 2009 Healthcare Conference in Boston.

Mr. Jackson will provide a corporate overview and an update on the company's progress with two ongoing Phase 2 clinical trials of CPX-351 in newly diagnosed acute myeloid leukemia (AML) patients and first-relapse AML patients. The presentation will be given on Thursday, September 10, 2009 at 1:30pm EDT in the Blaxton Room of the Four Seasons Hotel.

Source:

http://www.celatorpharma.com

Posted in: Drug Trial News

Comments (0)

Download PDF Copy

Suggested Reading

CURE GABA-A and Grann Pharmaceuticals announce global partnership to advance rare neurological therapies

Edible microbeads trap fat to support weight loss

Mushrooms deliver nutrition medicine and sustainability solutions in one package

COPD care pathways improve hospital outcomes and standardize treatment

Mentavi study validates first fully digital diagnostic pathway for adult ADHD

New treatment approach developed to prevent lupus nephritis

Gene editing restores hearing and balance in adult mice with DFNA41 deafness

Targeting gut signaling protein may protect against alcohol-related liver damage

Comments

The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.

Post a new comment

(Logout)

Post

Sign in to keep reading

We're committed to providing free access to quality science. By registering and providing insight into your preferences you're joining a community of over 1m science interested individuals and help us to provide you with insightful content whilst keeping our service free.